EE317 What Are the Lessons Learned From the Assessments of Economic Evaluations of Orphan Drugs Submitted by Manufacturers to the French National Authority for Health (HAS) From 2014 to 2024?
Abstract
Authors
S Ghabri F Simon
S Ghabri F Simon
ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now